In response to an article by Professor Philip Clarke in the Australian Financial Review titled Time to slash cost of generics, Medicines Australia Chief Executive Dr Brendan Shaw hit back saying that ‘the price of generic medicines on the Pharmaceutical Benefits Scheme (PBS) is already being reduced by as much as 70%.’
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- FDA approves third interchangeable insulin glargine biosimilar Langlara
- EMA recommends approval for ranibizumab biosimilar Rexatilux
- Japan approves Samsung-Nipro’s ustekinumab biosimilar
- FDA approves denosumab biosimilar Ponlimsi
Research
- Biosimilars uptake in Chile: why does it lags behind?
- Biosimilar aflibercept (AVT06) pre-filled syringe promises safer, faster eye injections
- OECD study finds no direct link between advertising rules and biosimilar uptake
- Reaching ESG goals in pharmaceutical development
- MORE EDITORIAL SECTIONS
- Search




Post your comment